Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting

The Link Between Anemia and Deficits in Memory and Attention in Individuals With Sickle Cell Disease

This study has been completed.
University of California, San Francisco
Information provided by:
National Heart, Lung, and Blood Institute (NHLBI) Identifier:
First received: March 23, 2007
Last updated: August 18, 2016
Last verified: October 2013
Sickle cell disease is an inherited blood disorder that affects red blood cells (RBCs). People with sickle cell disease frequently experience anemia, or a low number of RBCs. RBCs are responsible for carrying oxygen to the brain and other body tissues that need oxygen to function properly. The purpose of this study is to determine what changes, which were possibly caused by anemia, exist in the brains of individuals with sickle cell disease.

Sickle Cell Disease

Study Type: Observational
Official Title: Sickle-Cell Disease: Neuroimaging and Cognitive Decline

Resource links provided by NLM:

Further study details as provided by National Heart, Lung, and Blood Institute (NHLBI):

Enrollment: 120
Study Start Date: July 2006
Study Completion Date: February 2009
Primary Completion Date: February 2009 (Final data collection date for primary outcome measure)
Detailed Description:

The role of RBCs is to carry oxygen from the lungs to the brain and other body tissues. Individuals with anemia have unusually low numbers of RBCs. They also often have difficulty concentrating and remembering information, which is likely caused by a reduced oxygen supply to the brain. Previous research has shown that correcting anemia in patients without sickle cell disease improved their memory and attention. The purpose of this study is to examine any abnormal changes in the brains of individuals with sickle cell disease and to determine whether these changes are related to reduced memory and attention capabilities.

Participants will attend one study visit. During this visit, a brain magnetic resonance image (MRI) will be performed while participants complete neuropsychological tests that measure memory, attention, and organizational ability. There will be no follow-up visits.

The study completion date listed in this record was obtained from the "End Date" entered in the Protocol Registration and Results System (PRS) record.


Ages Eligible for Study:   21 Years and older   (Adult, Senior)
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   Yes

Inclusion Criteria:

  • Diagnosis of sickle cell disease

Exclusion Criteria:

  • Pregnancy
  • Claustrophobia
  • Mass lesion (e.g., meningioma, cyst, or spinal block)
  • Need for life support constant monitoring
  • Any unstable condition that is likely to require resuscitation
  • Presence of a pacemaker or other iron-containing magnetic substances in the body
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT00451919

United States, California
University of California San Francisco
San Francisco, California, United States, 94121
Sponsors and Collaborators
National Heart, Lung, and Blood Institute (NHLBI)
University of California, San Francisco
Principal Investigator: Randall R. Rule, PhD University of California, San Francisco
  More Information Identifier: NCT00451919     History of Changes
Other Study ID Numbers: 375  K01HL073152 
Study First Received: March 23, 2007
Last Updated: August 18, 2016
Health Authority: United States: Federal Government

Keywords provided by National Heart, Lung, and Blood Institute (NHLBI):

Additional relevant MeSH terms:
Anemia, Sickle Cell
Anemia, Hemolytic, Congenital
Anemia, Hemolytic
Hematologic Diseases
Genetic Diseases, Inborn processed this record on October 21, 2016